Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04865250
Title Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)
Acronym iReP
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Heidelberg
Age Groups: senior | adult
Covered Countries DEU

No variant requirements are available.